Companies To Watch: Freya Biosciences

By Wayne Koberstein, Executive Editor, Life Science Leader
Follow Me On Twitter @WayneKoberstein

Enlivening the longtime lonely space of reproductive health, starting with a new focus on the vaginal microbiome

SNAPSHOT
Freya Biosciences is a Danish company developing new vaginal microbial immunotherapies, with its lead candidate, coded FB101, about to enter Phase 2 to improve success of in vitro fertilization (IVF). FB101 targets the imbalance among constituents of the vaginal microbiome that causes local immune dysregulation and inflammation in the female reproductive tract. Other candidates are still in early discovery and preclinical development for a range of reproductive-health indications. The overall goal is to restore a normal vaginal microbiome and eliminate conditions that hinder or block women’s reproductive functions and undermine treatments such as in vitro fertilization (IVF).